Immutep (IMMP) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immutep is the larger company by market cap ($28.3 million vs $26.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | MCRB |
|---|---|---|
| Share price | $3.84 | $2.63 |
| Market cap | $28.30M | $26.42M |
| 1-day change | -6.56% | -3.31% |
| YTD return | +34.27% | — |
| 1-year return | +90.10% | — |
| 5-year return | -2.78% | — |
| EPS (TTM) | $-7.30 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $70.60 | $29.98 |
| 52-week low | $3.80 | $2.42 |
| Distance from 52-week high | -94.56% | -91.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +681.25% | +546.39% |
| Average volume | 14.70K | 72.00K |
| Shares outstanding | 7.37M | 10.04M |
| Employees | — | 66 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Healthcare · Biotechnology
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 66 employees
IMMP vs MCRB FAQ
Which is bigger, Immutep or Seres Therapeutics?
Immutep (IMMP) is larger, with a market capitalization of $28.30M compared with $26.42M for Seres Therapeutics (MCRB).
Are Immutep and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.